AFib ablation slashed progression risk; FDA panel pans empagliflozin for type 1 diabetes

ATTEST: AFib ablation slows progression to persistence By Mitchel Zoler   AFib ablation cut the rate of paroxysmal to persistent arrhythmia progression by 89%, compared with medical management.   You can take the MDedge Podcasts survey by clicking here.   Other stories:   FDA panel rejects new empagliflozin indication for type 1 diabetes Panelists voted 14-2 against the application and criticized the limited data supporting the application.   ACP recommends ways to address rising drug prices One of the College’s suggestions is for the Medicare Part D low-income subsidy program to be modified.   Drug spending driving up Part B premiums and deductibles The standard premium will climb 6.7% in 2020.   Methotrexate affected joint erosions, not pain, in patients with erosive hand OA The results were observed for 10 mg methotrexate per week at 3 months and 12 months.   You can contact the MDedge Daily Medical News by emailing us at [email protected] or following us on Twitter at @MDedgeTweets.